211 citations
,
May 2013 in “Journal of Nutrition Health & Aging” MK-0773 safely increased muscle mass but did not improve muscle strength or function in elderly women with sarcopenia.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
January 2022 in “Skin Pharmacology and Physiology” Higher STAT3 levels are found in hair loss areas, but not linked to hair loss severity.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.
March 2023 in “International Journal of Applied Pharmaceutics” The β-sitosterol hair gel is effective and promising for treating hair loss.
GLP-1 receptor agonists increase the risk of hair loss, mainly due to weight loss-related nutrient deficiency.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
7 citations
,
November 2023 in “JAAD Case Reports” Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.
22 citations
,
August 2020 in “Cells” TGM3 is important for skin and hair structure and may help diagnose cancer.
July 2026 in “Journal of Investigative Dermatology”
April 2016 in “Journal of Investigative Dermatology” A peptide known for reducing wrinkles also effectively inhibits an enzyme linked to skin inflammation and acne.
October 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” The new aptamer TAGX-0003 shows promise as an effective treatment for hair loss disorder alopecia areata.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
11 citations
,
June 2019 in “Journal of dermatology” New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
August 2022 in “Journal of Investigative Dermatology” Baricitinib reduces inflammation and mitochondrial damage in skin cells.
3 citations
,
June 2021 in “PLOS ONE” A topical BRAF inhibitor, vemurafenib, can speed up wound healing and promote hair growth, especially in diabetic patients.
159 citations
,
October 2015 in “Science Advances” Blocking JAK-STAT signaling can lead to hair growth.
September 2025 in “DiRROS repository (University of Maribor)” JAK inhibitors can effectively regrow hair in alopecia areata.
July 2026 in “American Journal of Clinical Dermatology” Oral JAK inhibitors help regrow hair in alopecia areata with manageable side effects.
April 2025 in “Scientific Reports” Astragaloside A may help fight lung cancer by targeting specific proteins.
December 2025 in “International Journal of Innovative Technologies in Social Science” Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
48 citations
,
July 2023 in “Pediatric Dermatology” Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
Ritlecitinib can reduce inflammation and help hair regrow in Alopecia Areata.
1 citations
,
June 2023 in “Advances in therapy” Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
3 citations
,
June 2021 in “Frontiers in genetics” The protein STAT3 slows down cell growth by blocking the FST gene, which affects hair development in sheep.
April 2017 in “Journal of Investigative Dermatology” Eating a lot of fat increases PKCβ and inflammation in skin fat cells, which affects skin and hair health.
November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
March 2024 in “International Journal of Pharmaceutics” Ginsenoside Rg3 combined with minoxidil was more effective in treating hair loss in mice.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.